As the National Institutes of Health continues to push its “All of Us” Research Program forward – an ambitious effort to gather data for over a million people living in the U.S to accelerate precision medicine research – medical professionals are also banding together to advance the science of precision health at the Powering Precision Health Summit (PPHS). After launching the conference last year, we are expecting that PPHS 2017 will be even bigger and more impactful, with over 500 attendees from around the world.
There was a thrilling energy in the air at last year’s Powering Precision Health Summit (PPHS) – a feeling that could only come from the sense of community and empowerment we experienced at the inaugural event. As the world’s first innovation-driven summit dedicated to transforming precision health, PPHS brought together key stakeholders across the healthcare community, including physicians, scientists, innovators, biopharma executives, patients and patient advocates, to tackle the world’s most pressing issues, as we move forward on the path to turn today’s reactive sick care into tomorrow’s preventative health care.
Imagine you’re in a field the size of Alaska. Now, imagine you’re tasked with finding one specific blade of grass in that field. Seems impossible, doesn’t it?
Enter Simoa, our single molecule array technology. Simoa is so sensitive that it allows scientists and researchers to see minute concentrations of biomarkers in blood and other bodily fluids at this equivalence.
Alzheimer’s disease is a dangerous and ultimately fatal form of dementia, and according to recent data from the Centers for Disease Control (CDC), Alzheimer’s is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths. What’s more, the CDC also reports that the number of deaths from Alzheimer’s disease in the United States has risen by 55% in the last 15 years alone. With the numbers on the rise, it’s more important than ever that we continue to accelerate research to advance treatment options for this and other progressive neurodegenerative diseases.
We had the privilege of hosting a webinar led by Dr. Jennifer E. Van Eyk, professor of medicine at Cedars-Sinai Medical Center. Jennifer has been a long-time friend and supporter of Quanterix and we were honored to have her share her expertise with attendees. During the webinar, Dr. Van Eyk discussed the need for precise protein quantification and identification to advance personalized medicine, which is a topic that is very near and dear to the work we do here at Quanterix. The future of healthcare relies on our ability to accelerate precision medicine to diagnose diseases before symptoms present.